Liang Chen

11PUBLICATIONS
20CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityProteins and peptidesNeurology and neuromuscular diseasesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 24, 2026
Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma.

Yan Zhu, Maoxuan Liu, Xiaokai Fan

|Nov 07, 2025
TRIM11 potentiates antitumor immunity via inhibition of the IFN-γ/PD-L1 axis.

Yingying Xu, Runjie Cai, Maoxuan Liu

|Aug 14, 2025
Targeted degradation of cell surface proteins through endocytosis triggered by cell-penetrating peptide-small molecule conjugates.

Wanyi He, Congli Chen, Jiwei Zheng

|Oct 28, 2022
TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells' killing.

Xuejia Feng, Gui Yang, Litian Zhang

|Aug 10, 2022
TRIM family proteins: roles in proteostasis and neurodegenerative diseases.

Yan Zhu, Lukman O Afolabi, Xiaochun Wan

|Jan 21, 2022
TRIM28 attenuates Bortezomib sensitivity of hepatocellular carcinoma cells through enhanced proteasome expression.

Jianchao Zhang, Xiaokai Fan, Lijuan Liao

Pageof 2

Frequent Collaborators

2 joint publications

Yanfeng Liu

2 joint publications

Lukman O Afolabi

2 joint publications

Xiaochun Wan

2 joint publications

Yan Zhu